SEC ownership of Beta Bionics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001674632.

Comparable stake leader

PRICE T ROWE ASSOCIATES INC /MD/

Disclosed value leader

PRICE T ROWE ASSOCIATES INC /MD/

Comparable rows

15/50

Latest evidence

11 Nov 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
15 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
PRICE T ROWE ASSOCIATES INC /MD/
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
11 Nov 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001674632
Issuer location
Irvine, CA

Ownership snapshot

Top shareholders of Beta Bionics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
PRICE T ROWE ASSOCIATES I...
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
15/50
Latest evidence
11 Nov 2026
13D/G 13F 3/4/5 Lead comparable stake: 17% 35 rows are not safely comparable across share classes. 13D/G row: PRICE T ROWE ASSOCIATES INC /MD/ Showing 1-8 of 50 holder rows.

Quick read

PRICE T ROWE ASSOCIATES INC /MD/ leads the comparable SEC ownership view at 17%.

15 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens PRICE T ROWE ASSOCIATES INC /MD/'s linked filing trail.
Comparable ownership Top 5
PRICE T ROWE ASSOCIATES INC /MD/ 17%
EVENTIDE ASSET MANAGEMENT, LLC 13%
Zone Healthcare Holdings, LLC 9.9%
Soleus Capital Group, LLC 9.8%
Soleus Capital Master Fund, L.P. 8.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
PRICE T ROWE ASSOCIATES INC /MD/
13D/G
T. Rowe Price Associates, Inc.
17%
Reported 13D/G · 30 Sep 2026
$169,741,981
8,943,061 shares
$0 30 Sep 2026
EVENTIDE ASSET MANAGEMENT, LLC
13F 13D/G
Company
13%
Reported 13D/G · 31 Mar 2026
$133,724,910
7,044,630 shares
— 30 Sep 2026
Zone Healthcare Holdings, LLC
13D/G
Dapice Joshua J.
9.9%
Reported 13D/G · 30 Sep 2025
$85,717,590
4,313,920 shares
+$17,618,729 30 Sep 2025
Soleus Capital Group, LLC
13D/G
Levy Guy
9.8%
Reported 13D/G · 31 Mar 2026
$38,580,879
4,354,501 shares
$0 31 Mar 2026
Soleus Capital Master Fund, L.P.
13D/G
Levy Guy
8.7%
Reported 13D/G · 30 Sep 2026
$91,550,616
4,828,619 shares
$0 30 Sep 2026
MORGAN STANLEY
13F 13D/G
Company
8.6%
Reported 13D/G · 30 Sep 2025
$82,210,844
4,331,446 shares
— 30 Sep 2026
Sands Capital Life Sciences Pulse Fund II, L.P.
13D/G
8.2%
Reported 13D/G · 30 Jun 2025
$48,410,732
3,570,113 shares
+$5,636,946 30 Jun 2025
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
8.1%
Reported 13D/G · 31 Mar 2026
$31,966,171
3,607,920 shares
-$6,839,920 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$4,634,215.

Buys
$0
Insiders: 0
Sells
$4,634,215
Insiders: 8
Net
-$4,634,215
Shares: -234,818
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 234,818
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 134,720 $0 $2,605,011 -$2,605,011
3-6 0 57,223 $0 $766,591 -$766,591
6-9 0 353 $0 $4,084 -$4,084
9-12 0 42,522 $0 $1,258,529 -$1,258,529

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-12 of 12 reporting-owner rows connected to Beta Bionics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
12
Largest Forms 3/4/5 holder
Sean Saint
Net 12M change
-$4.63MFull value: -$4,634,215 · USD · 12-month change
Latest report
11 Nov 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Sean Saint President & CEO, Director $7,999,577 -$744,510 -8.5% Filing P/S 03 Sep 2026
Mike Mensinger Chief Product Officer $3,844,280 -$583,769 -13% Filing P/S 27 Oct 2026
Steven Jon Russell Chief Medical Officer $3,242,116 -$163,973 -4.8% Filing P/S 02 Sep 2026
Stephen Feider Chief Financial Officer $2,742,162 -$1,186,512 -30% Filing P/S 11 Nov 2026
Mark Hopman Chief Commercial Officer $915,016 -$1,623,005 -64% Filing P/S 02 Nov 2026
Adam Lezack Director $591,679 -$62,680 -9.6% Mixed 21 May 2026
Christy Jones Director $449,972 -$228,214 -34% Filing P/S 22 Sep 2026
Gerard J. Michel Director $335,760 Mixed 21 May 2026
Danny L. Dearen Director $322,734 Mixed 21 May 2026
Sean Carney Director $322,734 Mixed 21 May 2026
Maria Palasis Director $294,557 -$41,552 -12% Mixed 21 May 2026
Wellington Hadley Harbor Aggregator IV, L.P. 10%+ Owner $78,032 Filing P/S 31 Jan 2025

Recent insider transactions for Beta Bionics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Stephen Feider BBNX Common Stock Sale -5.27% -$152,681 $17.21 -8,874 159,378 11 Nov 2026 Direct
Stephen Feider BBNX Common Stock Options Exercise 5.57% 8,874 168,252 11 Nov 2026 Direct
Stephen Feider BBNX Employee Stock Option (right to buy) Options Exercise -23% -8,874 29,695 11 Nov 2026 Direct
Stephen Feider BBNX Common Stock Sale -0.46% -$12,649 $17.00 -744 159,378 09 Nov 2026 Direct
Stephen Feider BBNX Common Stock Options Exercise 0.47% 744 160,122 09 Nov 2026 Direct
Stephen Feider BBNX Employee Stock Option (right to buy) Options Exercise -1.89% -744 38,569 09 Nov 2026 Direct
Stephen Feider BBNX Common Stock Sale -0.24% -$6,508 $17.04 -382 159,378 05 Nov 2026 Direct
Stephen Feider BBNX Common Stock Options Exercise 0.24% 382 159,760 05 Nov 2026 Direct
Stephen Feider BBNX Employee Stock Option (right to buy) Options Exercise -0.96% -382 39,313 05 Nov 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.68% -$6,253 $16.90 -370 54,143 02 Nov 2026 Direct
Mike Mensinger BBNX Common Stock Sale -1.49% -$58,300 $22.00 -2,650 174,740 27 Oct 2026 Direct
Mark Hopman BBNX Common Stock Sale -1.48% -$16,420 $20.00 -821 54,513 26 Oct 2026 Direct
Mark Hopman BBNX Common Stock Sale -1.38% -$13,446 $17.35 -775 55,334 14 Oct 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.66% -$7,015 $18.96 -370 56,109 01 Oct 2026 Direct
Christy Jones BBNX Common Stock Sale -24.7% -$147,890 $23.00 -6,430 19,564 22 Sep 2026 Direct
Mark Hopman BBNX Common Stock Sale -35.3% -$619,640 $20.13 -30,779 56,479 16 Sep 2026 Direct
Mike Mensinger BBNX Common Stock Sale -1.47% -$58,300 $22.00 -2,650 177,390 16 Sep 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.89% -$12,028 $15.52 -775 86,382 14 Sep 2026 Direct
Mark Hopman BBNX Common Stock Sale -29% -$664,550 $18.46 -35,994 88,033 09 Sep 2026 Direct
Sean Saint BBNX Common Stock Sale -1.4% -$113,259 $20.08 -5,641 398,429 03 Sep 2026 Direct
Mark Hopman BBNX Common Stock Sale -4.12% -$101,815 $19.11 -5,327 124,027 02 Sep 2026 Direct
Steven Jon Russell BBNX Common Stock Sale -2.43% -$80,676 $19.11 -4,221 169,628 02 Sep 2026 Direct
Mike Mensinger BBNX Common Stock Sale -2.37% -$83,620 $19.11 -4,375 180,040 02 Sep 2026 Direct
Stephen Feider BBNX Common Stock Sale -4.02% -$127,580 $19.11 -6,675 159,378 02 Sep 2026 Direct
Sean Saint BBNX Common Stock Sale -4.01% -$322,381 $19.11 -16,867 404,070 02 Sep 2026 Direct
Stephen Feider BBNX Common Stock Sale -2.86% -$83,381 $17.03 -4,896 166,053 29 Jun 2026 Direct
Stephen Feider BBNX Common Stock Options Exercise 2.95% 4,896 170,949 29 Jun 2026 Direct
Stephen Feider BBNX Employee Stock Option (right to buy) Options Exercise -11% -4,896 39,695 29 Jun 2026 Direct
Stephen Feider BBNX Common Stock Sale -2.98% -$87,006 $17.05 -5,104 166,053 26 Jun 2026 Direct
Stephen Feider BBNX Common Stock Options Exercise 3.07% 5,104 171,157 26 Jun 2026 Direct
Stephen Feider BBNX Employee Stock Option (right to buy) Options Exercise -10.3% -5,104 44,591 26 Jun 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.96% -$18,880 $15.01 -1,258 129,354 24 Jun 2026 Direct
Christy Jones BBNX Common Stock Sale -5.13% -$21,090 $15.00 -1,406 25,994 24 Jun 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.21% -$3,385 $12.31 -275 130,612 04 Jun 2026 Direct
Christy Jones BBNX Common Stock Sale -9.3% -$39,354 $14.00 -2,811 27,400 04 Jun 2026 Direct
Mike Mensinger BBNX Common Stock Sale -2.32% -$55,194 $12.61 -4,378 184,415 02 Jun 2026 Direct
Mark Hopman BBNX Common Stock Sale -3.91% -$67,183 $12.61 -5,329 130,887 02 Jun 2026 Direct
Steven Jon Russell BBNX Common Stock Sale -2.37% -$53,227 $12.61 -4,222 173,849 02 Jun 2026 Direct
Stephen Feider BBNX Common Stock Sale -3.87% -$84,165 $12.61 -6,676 166,053 02 Jun 2026 Direct
Sean Saint BBNX Common Stock Sale -3.85% -$212,707 $12.61 -16,872 420,937 02 Jun 2026 Direct
Adam Lezack BBNX Comon Stock Sale -3.51% -$11,188 $11.21 -998 27,399 22 May 2026 Direct
Gerard J. Michel BBNX Common Stock Award 102.5% 16,965 33,509 21 May 2026 Direct
Christy Jones BBNX Common Stock Award 128.1% 16,965 30,211 21 May 2026 Direct
Christy Jones BBNX Common Stock Sale -13.1% -$19,880 $9.95 -1,998 13,246 21 May 2026 Direct
Maria Palasis BBNX Common Stock Award 136.5% 16,965 29,397 21 May 2026 Direct
Danny L. Dearen BBNX Common Stock Award 111.3% 16,965 32,209 21 May 2026 Direct
Sean Carney BBNX Common Stock Award 111.3% 16,965 32,209 21 May 2026 Direct
Adam Lezack BBNX Common Stock Award 148.4% 16,965 28,397 21 May 2026 Direct
Adam Lezack BBNX Common Stock Sale -8.04% -$9,950 $9.95 -1,000 11,432 21 May 2026 Direct
Mark Hopman BBNX Common Stock Sale -0.25% -$4,084 $11.57 -353 139,133 04 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .